Wednesday, July 6, 2011
Sylentis SA, of Madrid, Spain, a subsidiary of Grupo Zeltia, presented two posters at the World Glaucoma Congress in Paris. One poster showed that topical candidate SYL040012, administered to healthy volunteers with normal intraocular pressure (IOP), demonstrated excellent local tolerance and showed a decline in IOP in most of the subjects.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.